Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$1.8 - $5.04 $159,948 - $447,854
-88,860 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$2.07 - $4.88 $644,059 - $1.52 Million
-311,140 Reduced 77.79%
88,860 $184,000
Q2 2019

Aug 14, 2019

SELL
$2.7 - $4.96 $202,500 - $372,000
-75,000 Reduced 15.79%
400,000 $1.98 Million
Q4 2018

Feb 14, 2019

BUY
$2.65 - $9.2 $1.26 Million - $4.37 Million
475,000 New
475,000 $1.38 Million

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Wexford Capital LP Portfolio

Follow Wexford Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Wexford Capital LP with notifications on news.